AxoGen Stock

AxoGen EV/EBIT

The EV/EBIT (Enterprise Value to EBIT) of AxoGen (AXGN) as of Aug 1, 2026 is -216.54. In the previous year, EV/EBIT (Enterprise Value to EBIT) was -966.81 — a change of -77.60% (higher).

EV/EBIT

-216.54

YoY

-77.60%

Last updated:

EV/EBIT (Enterprise Value to EBIT) of AxoGen is 2026 -216.54 . EV/EBIT (Enterprise Value to EBIT) of AxoGen was 2025 -966.81 . It decreases by -77.60% higher compared to the previous year.

The AxoGen EV/EBIT history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

PRICE-TO-EBIT
Date
PRICE-TO-EBIT
Jan 1, 2019
-22.49 base
Jan 1, 2020
-31.69 base
Jan 1, 2021
-15.16 base
Jan 1, 2022
-14.21 base
Jan 1, 2023
-14.16 base
Jan 1, 2024
-450.58 base
Jan 1, 2025
-195.69 base
Jan 1, 2026 (e)
-62.92 base
YEARPRICE-TO-EBIT
2026 est -62.92
2025 -195.69
2024 -450.58
2023 -14.16
2022 -14.21
2021 -15.16
2020 -31.69
2019 -22.49
2018 -37.36
2017 -120.46
2016 -36.05
2015 -16.15
2014 -8.25
2013 -8.14
2012 -3.85
2011 -4.29
2010 -8.14
2009 1.08
2008 -11.16
2007 -6.87
2006 -3.84
Access this data via the Eulerpool API

AxoGen Valuation

Details

Historical Valuation Multiples

Price-to-Earnings Ratio (P/E)

The P/E ratio divides AxoGen's share price by its earnings per share. It tells you how many years of current earnings you are "paying for" when you buy the stock. A P/E of 20 means you pay $20 for every $1 of annual earnings. The S&P 500 historically trades at an average P/E of roughly 15–17. A P/E significantly above that may signal high growth expectations; one below may indicate undervaluation — or declining business quality.

Price-to-Sales Ratio (P/S)

The P/S ratio divides market capitalization by total revenue. Unlike the P/E ratio, it works even for companies that are not yet profitable, making it essential for evaluating high-growth firms. A P/S below 1.0 may indicate undervaluation, while ratios above 10 are typically reserved for fast-growing tech or SaaS companies with high expected future margins.

Price-to-EBIT Ratio

This ratio relates AxoGen's market price to its operating earnings, excluding the effects of debt structure and tax jurisdiction. It is particularly useful for comparing companies across different countries or with different levels of leverage, because it focuses purely on operational profitability. Lower values suggest cheaper operational earnings.

How to Use This Chart

This chart plots AxoGen's valuation multiples over time. Compare the current P/E, P/S, and P/EBIT to their own historical averages — if the current ratio is well below the multi-year average, the stock may be relatively cheap compared to its own track record. Combine this with industry comparisons: a P/E that looks high in absolute terms may be justified if AxoGen grows earnings faster than its peers.

AxoGen Stock analysis

What does AxoGen do? AxoGen Inc is a US-American company based in Alachua, Florida. The company was founded in 2002 as a spin-off of the Grabowski Laboratory at the University of Florida. The goal of the company is to improve the regeneration of peripheral nerves through innovative products and solutions. AxoGen's business model is based on the development, production, and sale of biomaterial-based products for peripheral nerve regeneration. The company has three product categories: Avance nerve tissue, AxoGuard nerve wraps, and AxoTouch nerve testers. Avance nerve tissue is a proven technology for improving the regeneration of peripheral nerves. It consists of allogeneic nerve tissue from donors that has been prepared and sterilized for transplantation. Avance nerve tissue is used for surgical repair of nerve damage and has proven to be very effective in regenerating peripheral nerves. AxoGuard nerve wraps are silicone gels used for repairing nerve damage. They protect the delicate nerve fibers during the healing process and prevent scar formation. AxoGuard nerve wraps were designed to preserve the structure and function of nerves after surgical repair. AxoTouch nerve testers are devices used to measure nerve function. They are used to monitor and evaluate the integrity and function of peripheral nerves. This system is of great importance for assessing the surgical repair of nerve damage and monitoring the progress of healing. In recent years, AxoGen has experienced significant growth and has become a leading company in the field of peripheral nerve regeneration. The company has offices in the US and Europe and distributes its products worldwide. AxoGen is listed on the NASDAQ stock exchange and has a market capitalization of approximately $2.3 billion. AxoGen has made significant progress in recent years and has achieved several important milestones. In 2012, the company received approval from the US Food and Drug Administration (FDA) for the use of Avance nerve tissue for surgical repair of nerve damage. In 2014, AxoGen received CE marking for Avance nerve tissue and AxoGuard nerve wraps, thereby obtaining approval for the European market. AxoGen is continuously working on the development of new products and solutions to improve nerve regeneration. The company has a strong scientific foundation and is heavily involved in research. AxoGen also collaborates with leading scientists and clinics to improve its products and develop new applications. In summary, AxoGen is an innovative company specializing in the development and production of biomaterial-based products for peripheral nerve regeneration. The company has become a market leader in recent years and operates worldwide. AxoGen has brought proven technologies and products to the market that help improve nerve regeneration and enhance patients' quality of life. AxoGen is one of the most popular companies on Eulerpool.

Frequently Asked Questions about AxoGen stock

EV/EBIT (Enterprise Value to EBIT) of AxoGen is -216.54 in 2026.

Access this data via the Eulerpool API

Valuation — AxoGen

All Key Metrics — AxoGen